Vergara Chozas J M, Sáez-Benito Godino A, Zopeque García N, García Pinteño S, Joumady I, Carrasco García C, Vara Gil F
Hospital Universitario Puerta del Mar, Cádiz, Spain.
Transplant Proc. 2012 Nov;44(9):2669-72. doi: 10.1016/j.transproceed.2012.09.063.
Mycophenolic acid (MPA) is an immunosuppression agent for the prophylaxis of organ rejection in patients receiving allogeneic transplants. The drug is administered based in 2 formulations, mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS). MPA acts by specific, reversible, uncompetitive inhibition of inosine monophosphate dehydrogenase (IMPDH) and thus blocks the proliferation of both T- and B-activated lymphocytes. Therapeutic drug monitoring (TDM) constitutes an important part of immunosuppressive treatment because of the demonstrated significant intraindividual and interindividual variability of its pharmacokinetic behavior. TDM is required to optimize immunosuppressive efficacy. We present the analytical validation of a homogeneous particle-enhanced turbidimetric inhibition immunoassay (PETINIA) technique for determination of MPA in human plasma, and compare with a homogeneous enzyme immunoassay technique (EMIT; reference method), both methods adapted on a Dimension analyzer (Siemens). We examined 50 human plasma samples from kidney transplant recipients treated with MMF or EC-MPA, which were analyzed simultaneously by both methods. The interassay precision was 5.95% at a concentration of 1.0 μg/mL, 3.47% at 7.5 μg/mL, and 3.75% at 12.0 μg/mL. The bias of PETINIA-MPA for each of the 3 quality control sample was <3.0%. Least squares linear regression yielded an r-value of 0.994 with the following linear regression equation: PETINIA = 0.939 * EMIT - 0.063. Bland-Altman comparison presented a mean negative difference of -0.312 μg/mL (standard deviation [SD], 0.441), namely, -7.6% for PETINIA-MPA. The PETINIA assay for monitoring MPA concentrations is an acceptable method for routine clinical use, with interassay imprecision (% coefficient of variation) ranging from 5.9% to 3.7% below and above the therapeutic concentration range, respectively. In conclusion, MPA-EMIT and PETINIA-MPA methods on Dimension analyzer have a good correlation (r = 0.994), but PETINIA-MPA method demonstrates a negative average difference of -7.6% in comparison with EMIT-MPA method.
霉酚酸(MPA)是一种免疫抑制剂,用于预防接受同种异体移植患者的器官排斥反应。该药物有两种剂型,即霉酚酸酯(MMF)和肠溶包衣的霉酚酸钠(EC-MPS)。MPA通过特异性、可逆、非竞争性抑制肌苷单磷酸脱氢酶(IMPDH)发挥作用,从而阻断T淋巴细胞和B淋巴细胞的增殖。由于已证实其药代动力学行为存在显著的个体内和个体间差异,治疗药物监测(TDM)构成免疫抑制治疗的重要组成部分。需要进行TDM以优化免疫抑制效果。我们介绍了一种用于测定人血浆中MPA的均相颗粒增强比浊抑制免疫测定(PETINIA)技术的分析验证,并与均相酶免疫测定技术(EMIT;参考方法)进行比较,这两种方法均在Dimension分析仪(西门子)上进行了适配。我们检测了50份接受MMF或EC-MPA治疗的肾移植受者的人血浆样本,两种方法同时对其进行分析。在浓度为1.0μg/mL时,批间精密度为5.95%,在7.5μg/mL时为3.47%,在12.0μg/mL时为3.75%。PETINIA-MPA对3个质量控制样本中每个样本的偏差均<3.0%。最小二乘线性回归得出r值为0.994,线性回归方程如下:PETINIA = 0.939 * EMIT - 0.063。Bland-Altman比较显示平均负差值为-0.312μg/mL(标准差[SD],0.441),即PETINIA-MPA为-7.6%。用于监测MPA浓度的PETINIA测定法是一种可接受的常规临床使用方法,批间不精密度(变异系数%)在治疗浓度范围以下和以上分别为5.9%至3.7%。总之,Dimension分析仪上的MPA-EMIT法和PETINIA-MPA法具有良好的相关性(r = 0.994),但与EMIT-MPA法相比,PETINIA-MPA法显示出-7.6%的平均负差值。